Adverum Biotechnologies, Inc.
NASDAQ:ADVM
7.72 (USD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3.6 | 0 | 7.5 | 0 | 0.25 | 1.612 | 1.849 | 1.455 | 2.319 | 0.572 | 0.48 | 0.03 |
| Cost of Revenue
| 5.644 | 6.528 | 4.645 | 4.158 | 0 | 0 | 2.096 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -2.044 | -6.528 | 2.855 | -4.158 | 0.25 | 1.612 | -0.247 | 1.455 | 2.319 | 0.572 | 0.48 | 0.03 |
| Gross Profit Ratio
| -0.568 | 0 | 0.381 | 0 | 1 | 1 | -0.134 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 77.476 | 99.277 | 89.181 | 73.309 | 40.419 | 50.133 | 39.839 | 31.67 | 25.462 | 16.976 | 2.151 | 1.31 |
| General & Administrative Expenses
| 49.915 | 57.858 | 64.441 | 44.641 | 28.376 | 24.56 | 20.857 | 24.355 | 22.107 | 7.998 | 1.783 | 0.536 |
| Selling & Marketing Expenses
| -5.644 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 44.271 | 57.858 | 64.441 | 44.641 | 28.376 | 24.56 | 20.857 | 24.355 | 22.107 | 7.998 | 1.783 | 0.536 |
| Other Expenses
| 5.748 | 2.673 | 0.582 | 1.557 | 4.059 | 4.204 | 2.7 | 0.762 | 0.37 | -1.002 | -0.096 | -0.006 |
| Operating Expenses
| 121.747 | 157.135 | 153.622 | 117.95 | 68.795 | 74.693 | 60.696 | 56.025 | 47.569 | 24.974 | 3.454 | 1.816 |
| Operating Income
| -123.791 | -157.135 | -146.122 | -117.95 | -68.545 | -78.081 | -58.847 | -115.284 | -47.823 | -24.402 | -3.454 | -1.816 |
| Operating Income Ratio
| -34.386 | 0 | -19.483 | 0 | -274.18 | -48.437 | -31.826 | -79.233 | -20.622 | -42.661 | -7.196 | -60.533 |
| Total Other Income Expenses Net
| 5.548 | 2.673 | 0.582 | 1.557 | 4.059 | -0.796 | 2.7 | -59.952 | -2.203 | -1.002 | -1.749 | 0.013 |
| Income Before Tax
| -118.243 | -154.462 | -145.54 | -116.393 | -64.486 | -73.877 | -56.147 | -114.522 | -47.453 | -25.404 | -5.276 | -1.811 |
| Income Before Tax Ratio
| -32.845 | 0 | -19.405 | 0 | -257.944 | -45.829 | -30.366 | -78.709 | -20.463 | -44.413 | -10.992 | -60.367 |
| Income Tax Expense
| -1.078 | 0.074 | 4.408 | 1.114 | 1.401 | -1.25 | 0 | -0.775 | 1.761 | -0.162 | -0.023 | 0.002 |
| Net Income
| -117.165 | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 | -56.147 | -113.747 | -47.453 | -25.404 | -5.276 | -1.811 |
| Net Income Ratio
| -32.546 | 0 | -19.405 | 0 | -257.944 | -45.054 | -30.366 | -78.177 | -20.463 | -44.413 | -10.992 | -60.367 |
| EPS
| -11.62 | -15.57 | -14.85 | -13.8 | -10.06 | -1.18 | -1.29 | -3.14 | -1.86 | -1.12 | -0.25 | -0.087 |
| EPS Diluted
| -11.62 | -15.57 | -14.85 | -13.8 | -10.06 | -1.18 | -1.29 | -3.14 | -1.84 | -1.12 | -0.25 | -0.087 |
| EBITDA
| -118.147 | -150.607 | -141.477 | -113.792 | -66.972 | -66.331 | -56.751 | 6.144 | -42.677 | -24.402 | -3.524 | -1.821 |
| EBITDA Ratio
| -32.819 | 0 | -18.864 | 0 | -267.888 | -41.148 | -30.693 | 4.223 | -18.403 | -42.661 | -7.342 | -60.7 |